+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Next-Generation Cancer Diagnostics Market by Technology, Cancer Type, Application, Function - Forecast 2024-2030- Product Image
Global Next-Generation Cancer Diagnostics Market by Technology, Cancer Type, Application, Function - Forecast 2024-2030- Product Image
Sale

Global Next-Generation Cancer Diagnostics Market by Technology, Cancer Type, Application, Function - Forecast 2024-2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 5311174
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Next-Generation Cancer Diagnostics Market size was estimated at USD 9.77 billion in 2023, USD 12.02 billion in 2024, and is expected to grow at a CAGR of 24.12% to reach USD 44.36 billion by 2030.

The next-generation cancer diagnostics market encompasses the latest technological advancements in the tools, techniques, and methodologies utilized to detect and characterize cancers. This market focuses on innovations that offer enhanced accuracy, sensitivity, and specificity compared to traditional diagnostic methods. It includes genomic, proteomic, and epigenomic analysis, imaging techniques, and bioinformatics tools for early detection, prognosis, and cancer treatment monitoring. Several factors drive the expansion of next-generation cancer diagnostics, including the increasing global prevalence of cancer, advancements in genomic sequencing technologies, and the growing emphasis on personalized medicine.

Furthermore, government initiatives and funding for cancer research contribute significantly to market growth. Integrating artificial intelligence and machine learning in diagnostics also presents opportunities for enhanced precision in cancer detection and prognosis. Despite the promising development, the next-generation cancer diagnostics market faces several limitations and challenges. High costs associated with advanced diagnostic technologies can limit access to these tools, particularly in low- and middle-income countries. Moreover, the complexity of cancer biology and the variability in tumor types pose challenges in developing universally effective diagnostic solutions. Regulatory hurdles and the need for robust clinical validation also slow down the market's pace of innovation. However, recent developments in liquid biopsy, circulating tumor DNA (ctDNA) analysis, and non-invasive imaging techniques have opened new avenues for early cancer detection and monitoring. These advancements present significant opportunities for market growth. Moreover, the application of next-generation sequencing (NGS) in cancer diagnostics continues to evolve, offering the potential to discover novel biomarkers and therapeutic targets.

Regional Insights

In the Americas, particularly the United States, next-generation cancer diagnostics are experiencing rapid advancements, largely driven by significant investments in research and development. The focus is largely on precision medicine and non-invasive diagnostic techniques, such as liquid biopsies that detect circulating tumor DNA. The EMEA region shows a diverse landscape in adopting and developing next-generation cancer diagnostics. Europe leads within the region, with several countries incorporating genomic sequencing and biomarker analysis into standard cancer care, supported by strong healthcare systems and public healthcare policies.

The Middle East, particularly countries such as Israel and the United Arab Emirates, are rapidly emerging as innovative hubs for medical technology, including cancer diagnostics. Africa faces more challenges, including resource limitations, but progress is being made through international partnerships and initiatives to improve cancer care infrastructure and accessibility. The Asia-Pacific region is witnessing significant growth in the next-generation cancer diagnostics market, driven by rising cancer prevalence, growing healthcare expenditure, and a surge in awareness about early cancer detection. Japan, South Korea, China, and Australia are at the forefront, investing heavily in healthcare technology and research. China, in particular, has seen rapid advancements and high adoption rates of technologies such as AI-driven diagnostic tools. Additionally, the region benefits from several fast-growing biotech startups and strategic collaborations between global and local firms aiming to tailor cancer diagnostics to regional specificities.

Market Trends by Segment

  • Technology: Increasing demand across molecular diagnostics to identify mutations associated with cancer
  • Application: Deployment of diagnostic tools across therapeutic monitoring to track the effectiveness of cancer treatments

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

Genialis to Develop Biomarker-Based Cancer Diagnostic Models

Genialis, an AI-driven life sciences company, is working to develop the next generation of cancer diagnostics based on biomarkers. Through a targeted approach to cancer detection, these models can accurately identify and track cancer at the cellular level in order to make more individualized diagnoses. In addition to improving accuracy, these biomarker models are expected to reduce diagnostic costs and improve patient outcomes. As the field of personalized, precision oncology continues to grow, Genialis' work in developing biomarker-based diagnostic models has the potential to revolutionize how healthcare providers detect and treat cancer.

Thermo Fisher Scientific and Arsenal Biosciences Collaborate to Support Clinical Manufacturing of Autologous T-Cell Therapies

Thermo Fisher Scientific Inc. strategic collaboration to support clinical manufacturing of T-cell therapies. This union aims to unlock the power of next-generation cancer diagnostics, further therapy development, and increase access to curative drugs. Through this collaboration, both industry-leading companies will bring their expertise in process optimization, CMC development, and cell engineering to maximize production efficiency through automation and high-quality processes. This collective vision for better health outcomes indicates the ambition to develop more personalized treatments for cancer patients.

Pfizer shifts focus to oncology with USD 43 billion Seagen acquisition

Pfizer acquired cancer-focused biotechnology firm Seagen for a notable sum of USD 43 billion, positioning itself as a formidable player in the oncology field. Emphasizing the significance of innovation in cancer treatment, the acquisition notably enhances Pfizer's oncology portfolio by incorporating Seagen's advanced antibody-drug conjugate (ADC) technology. ADCs represent a rapidly expanding segment within cancer therapeutics, renowned for their precision in targeting and eradicating cancer cells while minimizing damage to surrounding healthy tissues.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agena Bioscience, Inc. by Mesa Laboratories, Inc., Agilent Technologies, Inc., Akadeum Life Sciences, Almac Group, Becton, Dickinson & Company, Bio-Techne Corporation, Biological Dynamics Inc., bioMérieux SA, BioNTech SE, Castle Biosciences Inc., Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare, Hologic Inc., Illumina, Inc., Johnson & Johnson Services, Inc., Konica Minolta, Inc., Koninklijke Philips N.V., NeoGenomics Laboratories, Novartis AG, OPKO Health, Inc., Oxford Nanopore Technologies Limited, Perkin Elmer, Inc., Qiagen N.V., Siemens Healthineers AG, Sysmex Corporation, Telerad Tech, and Thermo Fisher Scientific, Inc.

This research report offers invaluable insights into various crucial aspects of the Next-Generation Cancer Diagnostics Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Burden of Cancer Cases Globally and Need for Efficient Diagnostics
5.1.1.2. Growing Utilization of Microfluidic Chips in Cancer Management
5.1.1.3. Government Initiatives Towards Cancer Screening
5.1.2. Restraints
5.1.2.1. High Investment and Insufficient Standardization of Diagnostics
5.1.3. Opportunities
5.1.3.1. Proliferation of Personalized and Advanced Genome Medicine
5.1.3.2. Technological Advancements in Next-Generation Cancer Diagnostics
5.1.4. Challenges
5.1.4.1. Limitations and Risks Associated with NGC Diagnostics
5.2. Market Segmentation Analysis
5.2.1. Technology: Increasing demand across molecular diagnostics to identify mutations associated with cancer
5.2.2. Application: Deployment of diagnostic tools across therapeutic monitoring to track the effectiveness of cancer treatments
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter’s Five Forces Analysis
5.6.1. Threat of New Entrants
5.6.2. Threat of Substitutes
5.6.3. Bargaining Power of Customers
5.6.4. Bargaining Power of Suppliers
5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization
6. Next-Generation Cancer Diagnostics Market, by Technology
6.1. Introduction
6.2. Clustered Regularly Interspaced Short Palindromic Repeats Diagnostics
6.3. DNA Microarrays
6.4. Lab-on-a-Chip & Reverse Transcriptase-PCR
6.5. Molecular Diagnostics
6.6. Next Generation Sequencing
6.7. Protein Microarrays
6.8. qPCR & Multiplexing
7. Next-Generation Cancer Diagnostics Market, by Cancer Type
7.1. Introduction
7.2. Bladder Cancer
7.3. Breast Cancer
7.4. Cervical Cancer
7.5. Colorectal Cancer
7.6. Kidney Cancer
7.7. Lung Cancer
7.8. Pancreatic Cancer
7.9. Prostate Cancer
7.10. Thyroid Cancer
7.11. Uterine Cancer
8. Next-Generation Cancer Diagnostics Market, by Application
8.1. Introduction
8.2. Cancer Screening
8.3. Companion Diagnostics
8.4. Prognostics
8.5. Risk Analysis
8.6. Therapeutic Monitoring
9. Next-Generation Cancer Diagnostics Market, by Function
9.1. Introduction
9.2. Biomarker Development
9.3. CTC Analysis
9.4. Epigenetic Analysis
9.5. Genetic Analysis
9.6. Proteomic Analysis
10. Americas Next-Generation Cancer Diagnostics Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Next-Generation Cancer Diagnostics Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Next-Generation Cancer Diagnostics Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Genialis to Develop Biomarker-Based Cancer Diagnostic Models
13.3.2. Thermo Fisher Scientific and Arsenal Biosciences Collaborate to Support Clinical Manufacturing of Autologous T-Cell Therapies
13.3.3. Pfizer shifts focus to oncology with USD 43 billion Seagen acquisition
13.3.4. Ibex and Alverno Laboratories Sign Multi-Year, Multi-Tissue Expansion Agreement of AI for Cancer Diagnosis
13.3.5. Swansea biotech startup raises £1.5m for AI bowel cancer blood test
13.3.6. Precision for Medicine Accelerating Precision Oncology with Next Generation Screening to Support New Cancer Diagnostics
14. Competitive Portfolio
14.1. Key Company Profiles
14.2. Key Product Portfolio
List of Figures
FIGURE 1. NEXT-GENERATION CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 2. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. NEXT-GENERATION CANCER DIAGNOSTICS MARKET DYNAMICS
FIGURE 7. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 8. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
FIGURE 10. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 12. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
FIGURE 14. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 24. NEXT-GENERATION CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON-A-CHIP & REVERSE TRANSCRIPTASE-PCR, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON-A-CHIP & REVERSE TRANSCRIPTASE-PCR, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THYROID CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THYROID CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY UTERINE CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY UTERINE CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY REGION, 2024-2030 (USD MILLION)
TABLE 49. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 50. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 51. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 52. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 53. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
TABLE 54. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
TABLE 55. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2023 (USD MILLION)
TABLE 56. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2024-2030 (USD MILLION)
TABLE 57. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 58. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 59. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
TABLE 60. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
TABLE 61. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
TABLE 62. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
TABLE 63. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
TABLE 64. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
TABLE 65. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
TABLE 66. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
TABLE 67. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
TABLE 68. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
TABLE 69. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 70. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 71. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 72. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 73. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 74. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 75. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 76. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 77. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 78. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 79. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 80. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 81. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 82. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 83. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 84. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 85. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 86. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 87. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 88. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 89. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 90. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 91. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 92. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 93. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 94. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 95. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 96. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 97. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 98. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 99. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 100. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 101. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 102. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 103. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 104. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 105. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 106. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 107. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 108. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 109. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 110. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 111. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 112. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 113. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 114. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 115. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 116. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 117. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 118. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 119. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 120. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 122. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 124. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 126. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 128. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 130. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 131. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 132. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 133. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 134. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 135. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 136. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 137. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 138. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 139. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 140. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 141. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 142. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 143. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 144. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 145. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 146. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 147. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 148. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 149. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 150. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 151. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 152. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 153. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 154. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 155. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 156. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 157. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 158. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 159. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 160. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 161. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 162. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 163. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 164. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 165. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 166. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 167. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 168. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 169. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 170. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 171. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 172. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 173. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 174. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 175. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 176. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 177. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 178. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 179. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 180. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 181. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 182. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 183. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 184. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 185. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 186. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 187. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 188. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 189. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 190. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 191. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 192. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 193. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 194. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 195. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 196. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 197. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 198. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 199. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 200. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 201. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 202. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 203. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 204. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 205. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 206. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 207. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 208. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 209. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 210. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 211. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 212. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 213. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 214. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 215. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 216. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 217. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 218. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 219. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 220. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 221. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 222. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 223. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 224. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 225. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 226. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 237. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 238. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 239. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 240. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 241. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 242. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 243. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 244. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 245. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 246. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 247. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 248. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 249. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 250. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 251. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 252. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 253. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 254. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 255. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 256. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 257. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 258. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 259. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 260. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 261. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 262. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 263. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 264. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 265. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 266. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 267. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 268. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 269. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 270. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 271. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 272. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 273. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 274. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 275. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 276. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 277. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 278. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 279. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 280. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 281. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 282. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 283. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 284. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 285. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 286. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 287. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 288. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 289. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 290. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 291. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
TABLE 292. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
TABLE 293. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 294. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 295. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 296. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 297. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 298. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 299. NETHERLANDS

Companies Mentioned

  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Agena Bioscience, Inc. by Mesa Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Akadeum Life Sciences
  • Almac Group
  • Becton, Dickinson & Company
  • Bio-Techne Corporation
  • Biological Dynamics Inc.
  • bioMérieux SA
  • BioNTech SE
  • Castle Biosciences Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare
  • Hologic Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Konica Minolta, Inc.
  • Koninklijke Philips N.V.
  • NeoGenomics Laboratories
  • Novartis AG
  • OPKO Health, Inc.
  • Oxford Nanopore Technologies Limited
  • Perkin Elmer, Inc.
  • Qiagen N.V.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Telerad Tech
  • Thermo Fisher Scientific, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 12.02 Billion
Forecasted Market Value ( USD ) by 2030 $ 44.36 Billion
Compound Annual Growth Rate24.1%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Next Generation Cancer Diagnostics Market Size, Share & Trends Analysis Report By Technology (LOAC & RT-PCR, Protein Microarrays), By Application, By Cancer Type, By Function, By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Next Generation Cancer Diagnostics Market Size, Share & Trends Analysis Report By Technology (LOAC & RT-PCR, Protein Microarrays), By Application, By Cancer Type, By Function, By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 236 Pages
  • Global
From
Global Next-Generation Breast Cancer Diagnostic & Screening Market by Product, Diagnostic Technology, Screening Technology, Application, End User - Forecast 2024-2030 - Product Image

Global Next-Generation Breast Cancer Diagnostic & Screening Market by Product, Diagnostic Technology, Screening Technology, Application, End User - Forecast 2024-2030

  • Report
  • 194 Pages
  • Global
From
Global Next-Generation Gynecological Cancer Diagnostics Market by Components (Consumables, Instruments, Software), Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR)), Indication, End User - Forecast 2024-2030 - Product Image

Global Next-Generation Gynecological Cancer Diagnostics Market by Components (Consumables, Instruments, Software), Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR)), Indication, End User - Forecast 2024-2030

  • Report
  • 181 Pages
  • Global
From
Next Generation Cancer Diagnostics - Global Strategic Business Report - Product Image

Next Generation Cancer Diagnostics - Global Strategic Business Report

  • Report
  • 89 Pages
  • Global
From
Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Platform-based, Instrument-based), By Type (Imaging, Biopsy, Genomic Tests, Blood Tests), By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Platform-based, Instrument-based), By Type (Imaging, Biopsy, Genomic Tests, Blood Tests), By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 190 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.